5-[(叔丁氧基)羰基]-5-氮杂螺[2.3]己烷-1-羧酸 | 1251012-82-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 中文名称: 5-[(叔丁氧基)羰基]-5-氮杂螺[2.3]己烷-1-羧酸
• 英文名称: 5-(Tert-butoxycarbonyl)-5-azaspiro[2.3]hexane-1-carboxylic acid
• 英文别名: 5-[(2-methylpropan-2-yl)oxycarbonyl]-5-azaspiro[2.3]hexane-2-carboxylic acid
• CAS: 1251012-82-4
• 化学式: C₁₁H₁₇NO₄
• mdl: MFCD17016192
• 分子量: 227.26
• InChiKey: YHMUQYORLLKZHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.818
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• NAPHTHYRIDINES AS INHIBITORS OF HPK1
  申请人：Genentech, Inc.

  公开号：US20180282328A1

  公开（公告）日：2018-10-04

  Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

  萘啶化合物及其作为HPK1抑制剂的用途被描述。这些化合物在治疗HPK1依赖性疾病和增强免疫反应方面很有用。还描述了抑制HPK1的方法、治疗HPK1依赖性疾病的方法、增强免疫反应的方法以及制备萘啶化合物的方法。
• Indazolones as modulators of tnf signaling
  申请人：AbbVie Inc.

  公开号：US10160748B2

  公开（公告）日：2018-12-25

  The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.

  本公开提供了吲唑酮化合物、药学上可接受的盐、原药、生物活性代谢物、立体异构体和异构体，其中变量在本文中定义。本公开的化合物可用于治疗免疫学和肿瘤学疾病。
• Naphthyridines as inhibitors of HPK1
  申请人：Genentech, Inc.

  公开号：US10407424B2

  公开（公告）日：2019-09-10

  Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

  介绍了萘啶类化合物及其作为 HPK1 抑制剂的用途。这些化合物可用于治疗 HPK1 依赖性疾病和增强免疫反应。还描述了抑制 HPK1 的方法、治疗 HPK1 依赖性疾病的方法、增强免疫反应的方法以及制备萘啶化合物的方法。
• INDAZOLONES AS MODULATORS OF TNF SIGNALING
  申请人：AbbVie Inc.

  公开号：US20160304496A1

  公开（公告）日：2016-10-20

  The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.
• INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20210403479A1

  公开（公告）日：2021-12-30

  The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof, wherein R 1 , R 2 , R 3 , R 4 and A are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treating or preventing HIV infection in a subject.